Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CATX Perspective Therapeutics	$3.38 -6.4%	$3.79	$1.60 ▼ $16.31	$251.01M	1.17	930,662 shs	490,700 shs
DRTS Alpha Tau Medical	$3.36 -0.3%	$3.12	$2.11 ▼ $4.39	$285.00M	0.99	63,228 shs	31,012 shs
LUNG Pulmonx	$1.76 -5.4%	$2.38	$1.47 ▼ $9.37	$71.72M	0.43	458,348 shs	879,755 shs
OM Outset Medical	$13.92 -0.3%	$16.94	$5.85 ▼ $25.35	$247.36M	2.14	223,937 shs	91,775 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CATX Perspective Therapeutics	+0.28%	+6.80%	-12.38%	+33.70%	-76.39%
DRTS Alpha Tau Medical	+1.51%	+10.13%	+12.33%	+12.33%	+51.80%
LUNG Pulmonx	+5.08%	+23.18%	-39.81%	-41.88%	-75.49%
OM Outset Medical	-0.99%	+4.65%	-22.62%	-20.73%	+43.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CATX Perspective Therapeutics	1.4792 of 5 stars	3.6	1.0	2.0	0.8	0.0
DRTS Alpha Tau Medical	3.1387 of 5 stars	3.5	5.0	3.2	1.7	0.0
LUNG Pulmonx	3.9407 of 5 stars	4.3	4.0	2.6	3.3	0.6
OM Outset Medical	1.3446 of 5 stars	3.5	2.0	1.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CATX Perspective Therapeutics	3.18	Buy	$12.56	271.47% Upside
DRTS Alpha Tau Medical	3.00	Buy	$9.00	167.86% Upside
LUNG Pulmonx	2.56	Moderate Buy	$7.66	335.47% Upside
OM Outset Medical	3.00	Buy	$24.67	77.20% Upside

Current Analyst Ratings Breakdown

Latest LUNG, DRTS, CATX, and OM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	OM Outset Medical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$22.00
8/7/2025	OM Outset Medical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $22.00
8/1/2025	LUNG Pulmonx	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $3.00
7/31/2025	LUNG Pulmonx	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
7/31/2025	LUNG Pulmonx	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $5.00
7/31/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $16.00
7/31/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$9.00 ➝ $2.50
7/14/2025	OM Outset Medical	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$37.00
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
DRTS Alpha Tau Medical	N/A	N/A	N/A	N/A	$1.02 per share	N/A
LUNG Pulmonx	$83.79M	0.86	N/A	N/A	$1.70 per share	1.04
OM Outset Medical	$113.69M	2.18	N/A	N/A	$8.50 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	11/11/2025 (Estimated)
DRTS Alpha Tau Medical	-$31.75M	-$0.48	N/A	N/A	N/A	N/A	-51.21%	-38.18%	N/A
LUNG Pulmonx	-$56.39M	-$1.43	N/A	N/A	N/A	-62.88%	-69.76%	-36.26%	10/29/2025 (Estimated)
OM Outset Medical	-$127.98M	-$20.29	N/A	∞	N/A	-82.06%	-97.17%	-32.84%	11/5/2025 (Estimated)

Latest LUNG, DRTS, CATX, and OM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	DRTS Alpha Tau Medical	-$0.12	-$0.13	-$0.01	-$0.13	N/A	N/A
7/30/2025	Q2 2025	LUNG Pulmonx	-$0.40	-$0.38	+$0.02	-$0.38	$23.46 million	$23.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
DRTS Alpha Tau Medical	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
OM Outset Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CATX Perspective Therapeutics	N/A	9.60	9.60
DRTS Alpha Tau Medical	0.07	10.52	5.81
LUNG Pulmonx	0.54	5.35	4.63
OM Outset Medical	0.63	7.47	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CATX Perspective Therapeutics	54.66%
DRTS Alpha Tau Medical	2.65%
LUNG Pulmonx	91.04%
OM Outset Medical	N/A

Insider Ownership

Company	Insider Ownership
CATX Perspective Therapeutics	3.72%
DRTS Alpha Tau Medical	39.50%
LUNG Pulmonx	6.80%
OM Outset Medical	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CATX Perspective Therapeutics	70	74.26 million	65.21 million	Optionable
DRTS Alpha Tau Medical	80	84.82 million	51.32 million	No Data
LUNG Pulmonx	250	40.75 million	37.98 million	Optionable
OM Outset Medical	520	17.77 million	17.34 million	Not Optionable

LUNG, DRTS, CATX, and OM Headlines

Recent News About These Companies

T. Rowe Price Investment Management Inc. Makes New $17.73 Million Investment in Outset Medical, Inc. $OM

August 27 at 4:50 AM | marketbeat.com

Outset Medical (NASDAQ:OM) Given Sector Perform Rating at Royal Bank Of Canada

August 21, 2025 | marketbeat.com

Outset Medical's (OM) Sector Perform Rating Reaffirmed at Royal Bank Of Canada

August 21, 2025 | americanbankingnews.com

Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference

August 20, 2025 | globenewswire.com

Outset Medical, Inc. $OM Shares Sold by National Bank of Canada FI

August 19, 2025 | marketbeat.com

Outset Medical’s Earnings Call Highlights Strong Growth

August 15, 2025 | theglobeandmail.com

Outset Medical (OM) Receives a Hold from Oppenheimer

August 15, 2025 | theglobeandmail.com

Outset Medical Inc.

August 15, 2025 | barrons.com

After Plunging 26.8% in 4 Weeks, Here's Why the Trend Might Reverse for Outset Medical (OM)

August 15, 2025 | zacks.com

Outset Medical (NASDAQ:OM) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

August 8, 2025 | marketbeat.com

What To Expect From Outset Medical Inc (OM) Q2 2025 Earnings

August 7, 2025 | finance.yahoo.com

Outset Medical Reports Strong Q2 Growth and Raises Guidance

August 7, 2025 | msn.com

Outset Medical, Inc. (OM) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2025 | zacks.com

Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

August 6, 2025 | globenewswire.com

Uncovering Potential: Outset Medical's Earnings Preview

August 5, 2025 | benzinga.com

TD Asset Management Inc Acquires New Stake in Outset Medical, Inc. (NASDAQ:OM)

August 5, 2025 | marketbeat.com

Outset Medical Appoints Brittni McGill as Chief Nursing Officer to Enhance Dialysis Care Innovation

July 30, 2025 | quiverquant.comQ

Outset Medical Names First Chief Nursing Officer

July 30, 2025 | globenewswire.com

Outset Medical (OM) Projected to Post Earnings on Wednesday

July 30, 2025 | marketbeat.com

Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

July 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LUNG, DRTS, CATX, and OM Company Descriptions

Perspective Therapeutics NYSE:CATX

$3.38 -0.23 (-6.37%)

Closing price 04:00 PM Eastern

Extended Trading

$3.40 +0.02 (+0.74%)

As of 05:35 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Alpha Tau Medical NASDAQ:DRTS

$3.36 -0.01 (-0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$3.26 -0.10 (-2.95%)

As of 04:11 PM Eastern

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Pulmonx NASDAQ:LUNG

$1.76 -0.10 (-5.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 +0.01 (+0.85%)

As of 04:46 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Outset Medical NASDAQ:OM

$13.92 -0.04 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$13.91 -0.01 (-0.07%)

As of 04:11 PM Eastern

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time